Quotient Sciences has been recognized as a 2025 CDMO Leadership Awards winner in the category of Small Molecule Dosage Form – Global. The company is also a finalist for a champion award in the same category, with the award ceremony presented in March. The CDMO Leadership Awards recognize the best contract development and manufacturing organizations (CDMOs) across global and regional categories, with some changes implemented for 2025.
“For the 14th annual Outsourced Pharma CDMO Leadership Awards, we’ve added innovation to the way we select award winners, and excitement to how we will reveal those winners. The innovation comes with new award categories and enhanced scoring methodology.” said Louis Garguilo, Chief Editor, Outsourced Pharma, about the changes to this year’s awards.
More than 210 CDMOs were evaluated by customers from global pharma and biotech companies based on their work with providers on an outsourced project within the past 24 months. Sponsors provide their ratings of contract development and manufacturing organizations based on their recent projects, and feedback is reviewed to determine leading CDMOs in each category. New for 2025 are categories based on outsourcing need, in the areas of: Biologics, Cell & Gene Therapy, Small Molecule API, and Small Molecule Dosage Form.
“We are thrilled to introduce our 2025 CDMO Leadership Awards finalists to the Outsourcing community, and honored to offer such an important tool for drug sponsors in selecting their best-fit partner to help bring life-saving therapies to market,” said Outsourced Pharma Chief Editor Louis Garguilo. “The new categories and enhanced scoring methodology that went into this year’s appraisal bring an improved experience for drug sponsors using the resource as well as an ever-so-coveted distinction for the CDMOs. The unveiling of the award champions during our celebration in March will be an exciting new addition to the festivities.”
See the full list of nominees and winners presented by Outsourced Pharma and Life Science Leader
